# BPC-157 FAQ: Frequently Asked Questions on the Research Literature

> BPC-157 frequently asked questions — mechanism, safety, regulatory status, pharmacokinetics, and the state of human evidence, answered directly from the peer-reviewed literature.

## Frequently Asked Questions

**What is BPC-157?**
A synthetic 15-amino-acid peptide (pentadecapeptide) derived from a protein found in human gastric juice. Its full name is Body Protection Compound 157. It has a molecular weight of 1,419.5 daltons and is stable in the gastric environment. Most of the research literature was generated in the 1993-2026 period by the Sikiric laboratory in Zagreb, with a small but growing body of independent replication.

**What does BPC-157 do in the body?**
In rodent studies, BPC-157 upregulates VEGFR2 expression and activates the VEGFR2-Akt-eNOS signaling pathway, driving angiogenesis and nitric oxide production [1]. It also disrupts the Caveolin-1/eNOS inhibitory complex [2] and upregulates growth hormone receptor in fibroblasts via JAK2 [3]. In human subjects, no validated mechanism study has been conducted.

**What is BPC-157 used for in research?**
Animal research covers tendon and ligament healing [4][5], muscle repair [6], spinal cord injury recovery [7], hippocampal ischemia neuroprotection [8], cardiac cytoprotection [9], hepatoprotection [10], colocutaneous fistula healing [11], and multi-tissue wound healing [12]. Human pilot data exists for interstitial cystitis [20] and chronic knee pain [16] — both small, uncontrolled, and preliminary.

**What does BPC-157 stand for?**
Body Protection Compound-157. The number identifies it as the 157th amino acid sequence screened in the original Sikiric laboratory gastric protein fractionation work in the early 1990s.

**How does BPC-157 work?**
The three primary proposed mechanisms are: VEGFR2 upregulation and angiogenesis promotion [1]; disruption of the Caveolin-1/eNOS inhibitory complex, releasing nitric oxide production [2]; and growth hormone receptor upregulation in fibroblasts via JAK2, amplifying local GH-driven tissue repair [3]. Broader modulation of prostaglandin and all three NOS isoforms has also been documented [7][15].

**Is BPC-157 safe?**
Animal studies report no lethal dose in any published study and no serious organ toxicity [12]. Three small human pilot studies (total enrollment approximately 26 subjects) reported no adverse events [16][20]. No large-scale human safety trial has been conducted. The primary theoretical concern is VEGFR2-driven angiogenesis in oncological contexts, which is an active debate in the literature [18].

**Is BPC-157 FDA approved?**
No. BPC-157 has no FDA-approved indication and holds no IND status. It is classified as an unapproved new drug in the United States. The FDA has issued warnings about peptide products sold outside the drug approval process. Human use is not authorized by the FDA.

**Is BPC-157 legal?**
Legal status varies by jurisdiction. In the United States, BPC-157 cannot be legally sold for human use; it is an unapproved drug. In competitive sport, it is prohibited under WADA S0 regardless of jurisdiction.

**Is BPC-157 banned?**
Yes. BPC-157 is listed on the WADA Prohibited List under S0 (Non-Approved Substances), prohibited at all times in- and out-of-competition. USADA has sanctioned athletes for its use, including a one-year ban for a speed skater in 2024 and a four-year ban for a volleyball player. No Therapeutic Use Exemption is available.

**Is BPC-157 a steroid?**
No. BPC-157 is a peptide — a short amino acid chain — with no steroidal ring structure. It does not bind androgen, estrogen, or glucocorticoid receptors.

**Is BPC-157 a growth hormone?**
No. BPC-157 is a 15-amino-acid pentadecapeptide, not a 191-amino-acid pituitary hormone. One study found BPC-157 upregulates growth hormone receptor in tendon fibroblasts [3], amplifying the response to GH when GH is present — a receptor-sensitizing effect, not direct GH secretion.

**How long does BPC-157 stay in your system?**
In the most detailed published pharmacokinetic study, elimination half-life was 15.2 minutes in rats (IV) and 5.27 minutes in beagle dogs (IV) [19]. Intramuscular bioavailability ranged from 14-51% depending on species. No validated human pharmacokinetic study has been published.

**How long does BPC-157 take to work?**
Rodent studies report measurable tissue repair acceleration within 7-14 days of daily dosing in tendon, ligament, and muscle models [4][6]. In neurological models, functional recovery was observed within 24-72 hours of a single local application [8]. No validated human timeline data exists.

**Does oral BPC-157 work?**
In rodent studies, oral administration of BPC-157 has shown efficacy in gastrointestinal models [11] and ligament healing [4] at the same dose levels as intraperitoneal injection. Whether systemic tissue-repair effects from oral dosing match IP injection in musculoskeletal or neurological models has not been directly compared in published literature.

**How to reconstitute BPC-157?**
Published research protocols dissolve lyophilized BPC-157 in bacteriostatic water, typically at 1-2 mg/mL. This describes standard laboratory methodology as documented in published methods sections, not a protocol for human use.

**Is BPC-157 hard on the kidneys?**
Animal studies have not shown nephrotoxicity. A 2025 ischemia-reperfusion study found BPC-157-treated rats showed significantly lower renal injury scores compared to untreated injury controls, with restored antioxidant enzyme activity [13]. No validated human renal safety data exists.

**Can BPC-157 affect heart health?**
Rodent cardiac models show cardioprotective effects: BPC-157 at 10 μg/kg IP counteracted myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis in multiple rat models [9]. Human cardiac safety has not been evaluated.

**Does BPC-157 damage the liver?**
Published animal studies show hepatoprotective effects: BPC-157 prevented hepatic necrosis and fatty change and normalized AST/ALT in multiple liver injury models in rats [10]. No hepatotoxic signal has been published in the BPC-157 animal literature.

**Does BPC-157 cause cancer?**
No published in vivo study has shown BPC-157 promotes tumor growth. The VEGFR2 upregulation and pro-angiogenic mechanism raises a theoretical concern in oncological contexts. This is an active debate in the literature as of 2025 and remains scientifically unresolved [18].

**Does BPC-157 build muscle?**
Not as a direct anabolic agent. BPC-157 consistently accelerates recovery after muscle injury in rodent models [6][14]. No study has examined direct muscle anabolism in healthy uninjured animals.

**Does BPC-157 help with weight loss?**
No dedicated weight-loss studies exist in the BPC-157 literature. No study has examined BPC-157 in a healthy-subject weight management context.

**Does BPC-157 increase testosterone?**
No direct androgenic action has been identified in the BPC-157 literature. No study has documented changes in circulating testosterone in BPC-157-treated animals.

**What is the downside of taking peptides?**
For BPC-157 specifically: theoretical VEGFR2-driven angiogenesis in oncological contexts; unknown long-term effects; absence of validated human pharmacokinetic and safety data. More broadly, unregulated peptide preparations carry unknown purity and sterility risks.

**How to take BPC-157 and TB-500 together?**
Human co-administration protocols do not exist in the published literature. Both are prohibited under WADA S0 at all times.

**Is BPC-157 worth it?**
The preclinical record is large, internally consistent, and covers multiple tissue types. Human data is sparse — three small pilot studies, no completed large-scale RCT. BPC-157 is not FDA-approved, carries a WADA prohibition, and the oncological safety debate remains unresolved. The evidence base is substantive but preliminary [16][17].

## References

[1] Hsieh MJ, et al. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966
[2] Hsieh MJ, et al. Sci Rep. 2020;10(1):17078. PMID: 33051481
[3] Chang CH, et al. Molecules. 2014;19(11):19066-19077. PMID: 25415472
[4] Cerovecki T, et al. J Orthop Res. 2010;28(9):1155-1161. PMID: 20225319
[5] Krivic A, et al. J Orthop Res. 2006;24(5):982-989. PMID: 16583442
[6] Pevec D, et al. Med Sci Monit. 2010;16(3):BR81-88. PMID: 20190676
[7] Perovic D, et al. Curr Issues Mol Biol. 2022;44(5):1976-2004. PMID: 35678659
[8] Vukojević J, et al. Brain Behav. 2020;10(7):e01726. PMID: 32558293
[9] Sikiric P, et al. Biomedicines. 2022;10(11):2696. PMID: 36359218
[10] Sikiric P, et al. Life Sci. 1993;53(4):PL291-PL296. PMID: 7901724
[11] Klicek R, et al. J Pharmacol Sci. 2008;108(1):7-17. PMID: 18818478
[12] Seiwerth S, et al. Front Pharmacol. 2021;12:627533. PMID: 34267654
[13] Demirtas H, et al. Medicina (Kaunas). 2025;61(2):291. PMID: 40005408
[14] Staresinic M, et al. Biomedicines. 2022;10(12):3221. PMID: 36551977
[15] Sikiric P, et al. Gut Liver. 2020;14(2):173-186. PMID: 31158953
[16] Vasireddi N, et al. HSS J. 2025. DOI: 10.1177/15563316251355551
[17] Yuan C, et al. Int J Mol Sci. 2026;27(6):2876. PMID: 41898733
[18] Sikiric P, et al. Pharmaceuticals. 2025;18(10):1450. PMID: 41155565
[19] He L, et al. Front Pharmacol. 2022;13:1026182. PMID: 36588717
[20] Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis. Altern Ther Health Med. 2024.

---

A dark-botanical reading of the BPC-157 preclinical record — thirty years of tissue-repair findings, set in ink, cited to the source, and sold by no one.